Voreloxin News and Research

RSS
Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.
FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Investment report on Sunesis Pharmaceuticals

Investment report on Sunesis Pharmaceuticals

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals raises $5.0 million through private placement

Sunesis Pharmaceuticals raises $5.0 million through private placement

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

NASDAQ issues noncompliance letter to Sunesis Pharmaceuticals

NASDAQ issues noncompliance letter to Sunesis Pharmaceuticals

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer